# GSK plc 28.3% potential upside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/gsk-plc-28-3-potential-upside-indicated-by-deutsche/4121163353
- Published: 2024-07-01T13:24:57+01:00
- Author: Charlotte Edwards

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
with ticker ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
now has a potential upside of 28.3% according to Deutsche.
GSK.LDeutsche set a target
price of 1,950 GBX for the company, which when compared to the GSK plc share price
of 1,520 GBX at opening today (01/07/2024) indicates a potential upside of 28.3%.
Trading has ranged between 1,303 (52 week low) and 1,824 (52 week high) with an 
average of 9,119,869 shares exchanging hands daily. The market capitalisation at
the time of writing is £62,995,819,164.GSK plc is a global biopharma company. The
Company’s segments include Commercial Operations and Research and Development. It
develops cancer medicines for patients, including ovarian cancer, endometrial cancer,
and multiple myeloma. Its product areas include vaccines, specialty medicines, and
general medicine. It is also focused on addressing the unmet treatment needs of 
patients with respiratory and inflammatory conditions. Its vaccine portfolio includes
over 20 vaccines that help to protect people from a range of diseases and infections,
including meningitis, shingles and flu, among others. Its specialty medicines are
also engaged in developing medicines for respiratory disease and HIV. Its general
medicines include inhaled medicines for asthma and chronic obstructive pulmonary
disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide
therapeutics in chronic hepatitis B and steatotic liver disease as well as other
therapeutic areas beyond liver disease.

Share on: